VEGFA G-634C — The Angiogenesis Adapter
The VEGFA gene encodes vascular endothelial growth factor A11 vascular endothelial growth factor A
The master regulator of angiogenesis (new blood vessel formation), critical for oxygen delivery to tissues,
the master regulator of angiogenesis — the formation of new blood vessels. This
promoter variant, located at position -634 in the gene's regulatory region,
directly affects how much VEGF-A your cells produce. The C allele increases
VEGF-A expression, leading to higher circulating levels and greater angiogenic
potential. The G allele results in lower baseline VEGF production.
This SNP is one of only three genetic variants with replicated findings22 replicated findings
Among 99 unique polymorphisms studied in football players, only ACTN3 R577X, ACAN rs1516797, and VEGFA rs2010963 showed consistent associations across independent cohorts
across independent cohorts of professional football players — making it among
the most robust findings in sports genetics. But its implications extend far
beyond athletics: VEGF levels influence wound healing, cardiovascular health,
exercise adaptation, and soft tissue injury susceptibility.
The Mechanism
The -634G>C polymorphism sits in the 5′-untranslated region of the VEGFA gene,
a regulatory region that controls gene expression33 gene expression
Transcription rates determine how much protein gets made from a gene.
The C allele enhances promoter activity, resulting in higher VEGFA mRNA levels
and increased protein production. Functional studies44 Functional studies
Vailati et al. 2012 — analysis of 53 human retinal samples
show that C-allele carriers (CC or CG genotypes) have significantly higher VEGFA
gene expression than GG individuals (5.15 and 3.72 arbitrary units vs 2.62,
P=0.045).
VEGF-A is the central angiogenic factor in skeletal muscle. During exercise,
muscle contraction triggers VEGF release into the muscle interstitium55 muscle interstitium
The fluid-filled space between muscle fibers and capillaries,
where it binds to VEGF receptors on capillary endothelial cells. This stimulates
two forms of capillary growth: sprouting angiogenesis66 sprouting angiogenesis
New capillaries bud from existing vessels through endothelial cell proliferation and basement membrane remodeling
(driven by VEGF signaling) and longitudinal splitting77 longitudinal splitting
A capillary lumen splits into two parallel vessels through mechanical stretching of endothelial cells
(driven by shear stress and nitric oxide). Higher baseline VEGF production in
C-allele carriers means a stronger angiogenic response to training stimuli.
But VEGF also upregulates matrix metalloproteinases88 matrix metalloproteinases
MMPs — enzymes that degrade extracellular matrix proteins including collagen
(MMPs), which are necessary for capillary growth but also weaken the
extracellular matrix (ECM). Since more than 80% of muscle force99 more than 80% of muscle force
Force transmission research shows lateral force transfer to ECM is critical for strength
is transmitted laterally to the ECM rather than along the muscle fiber, excessive
MMP activity may impair force transmission. This explains why GG individuals —
with lower VEGF and thus lower MMP activity — show superior strength gains from
resistance training.
The Evidence
The most rigorous evidence comes from a within-subject crossover study1010 within-subject crossover study
Pickering et al. 2023 — 30 healthy men completed both resistance and endurance training in random order
where 30 healthy men completed both resistance training (4 weeks of knee
extensions at 80% 1-RM) and endurance training (4 weeks of cycling at 70-90%
max heart rate), separated by a 3-week washout. VEGFA rs2010963 GG homozygotes
increased maximum strength by +20.9% after resistance training but only
+8.4% in VO₂peak after endurance training (P=0.005). In contrast, C-allele
carriers gained only +12.2% strength — significantly less than GG individuals
(P=0.04) — though their endurance improvements were comparable.
The authors propose that lower VEGF in GG individuals preserves ECM integrity during resistance training, allowing more effective lateral force transmission and greater hypertrophy. C-allele carriers' higher VEGF drives angiogenesis but also MMP-mediated ECM degradation, blunting their strength response.
For injury risk, the evidence is equally compelling. A meta-analysis1111 meta-analysis
Zhang et al. 2024 — systematic review of 4 studies with 1,061 cases and 986 controls
of tendon and ligament injuries found that in European populations, the CC
genotype conferred OR 1.40 (95% CI 1.00-1.94, P=0.049) for injury risk
compared to GG. The C allele itself showed OR 1.15 (95% CI 1.00-1.32, P=0.045),
with the G allele demonstrating protective effects. Specifically, rs2010963 CC1212 rs2010963 CC
Systematic review of genetic predisposition to injury in football
homozygotes had greater risk of ACL and ligament/tendon injury than G-allele
carriers, replicated across two independent football cohorts.
The mechanism is likely tied to VEGF's role in tissue healing1313 tissue healing
VEGF is highly expressed 2-3 weeks post-ACL surgery and critical for graft remodeling.
While adequate angiogenesis is necessary for tendon repair, excessive VEGF
upregulates MMPs that degrade collagen, weakening connective tissue structure.
CC individuals' chronically higher VEGF may predispose to tendon/ligament
fragility under load.
Training Adaptations
The GG genotype confers a clear advantage for resistance training. The +20.9% strength gain in GG individuals versus +12.2% in C-allele carriers represents a 71% greater adaptation to the same training stimulus. This is among the largest effect sizes for any single SNP in exercise genetics.
For endurance training, the picture is more nuanced. C-allele carriers have
higher circulating VEGF and greater angiogenic potential, which theoretically
should enhance capillary density and oxygen delivery. Some studies report
better aerobic capacity1414 better aerobic capacity
C allele associated with higher VO₂max values in some cohorts
in C-allele carriers. However, the crossover study found no significant
difference in VO₂peak gains between genotypes (+8-9% for both). This may
reflect that angiogenesis, while important, is just one of many adaptations
to endurance training (mitochondrial biogenesis, fiber-type shifts, etc.).
Injury Prevention
For C-allele carriers — particularly CC homozygotes — soft tissue injury risk is elevated. This is especially relevant for athletes in high-stress sports (football, basketball, skiing) where ACL and tendon injuries are common. The OR 1.40 for CC versus GG translates to roughly 40% higher odds of injury per exposure event, though absolute risk depends on sport, training load, and biomechanics.
Interactions
VEGFA rs2010963 is part of a functional haplotype with two other promoter SNPs:
rs6999471515 rs699947
-2578C/A polymorphism in VEGFA promoter
(-2578C/A) and rs15703601616 rs1570360
-1154G/A polymorphism in VEGFA promoter
(-1154G/A). The A-G-G haplotype (rs699947-rs1570360-rs2010963) has been
associated with increased risk of chronic Achilles tendon injury. Individuals
carrying multiple high-VEGF alleles across these SNPs may have compounded
angiogenic drive and correspondingly greater MMP activity.
The interplay with nitric oxide1717 nitric oxide
NO is produced by endothelial NOS in response to shear stress and by neuronal NOS during muscle contraction
(NO) is also critical. NO and VEGF work synergistically: VEGF upregulates
endothelial NOS (eNOS), and NO in turn enhances VEGF receptor sensitivity.
Genetic variants affecting NO production (e.g., NOS31818 NOS3
Endothelial nitric oxide synthase gene polymorphisms
polymorphisms) may modulate the phenotypic effects of VEGFA rs2010963.